Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis
Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis
复制标题
绝经后骨质疏松症患者既往骨质疏松症治疗时间对罗莫佐单抗疗效的影响
DOI：
10.1007/s00198-022-06545-1
复制
发表时间：
2022
影响因子：
4
通讯作者：
Nakata Ken
中科院分区：
文献类型：
--
作者：
Ebina Kosuke;Etani Yuki;Tsuboi Hideki;Nagayama Yoshio;Kashii Masafumi;Miyama Akira;Kunugiza Yasuo;Hirao Makoto;Okamura Gensuke;Noguchi Takaaki;Takami Kenji;Goshima Atsushi;Miura Taihei;Fukuda Yuji;Kurihara Takuya;Okada Seiji;Nakata Ken
我们读了Tominaga等人写的论文。[1]标题为“先前骨质疏松症治疗的持续时间对romosozumab治疗效果的影响”，发表在6月号的《国际骨质疏松症》上。他们的结论表明，口服双膦酸盐（BP）或狄诺塞单抗（DMAb）治疗> 1年，可通过腰椎（LS）骨矿物质密度（BMD）的变化而非全髋（TH）骨矿物质密度（BMD）的变化来评估罗莫珠单抗（ROMO）的作用。这一发现具有影响力，特别是在BP和DMAb的治疗开始和持续时间方面。我们报告了ROMO的治疗反应[2，3]，并类似地分析了有关既往骨质疏松治疗持续时间影响的数据。在他们的报告[1]中，平均年龄为77.2岁，BMD T评分为LS=-2.4，TH=-2.4。然而，我们组的平均年龄为74.5岁，BMD T评分为LS=-3.1，TH=-2.6（补充表1）[2]。既往BP或DMAb治疗≤ 12个月的持续时间相似。将患者分为5组：既往未治疗组（n= 55）、BP≤ 12个月组（n= 10）、BP> 12个月组（n= 27）、DMAb≤ 12个月组（n= 16）和DMAb> 12个月组（n= 29）。两个BP组，无论之前的BP持续时间如何，都显示出类似的总N-末端I型前胶原前肽（PINP）的短暂增加，以及抗酒石酸酸性磷酸酶（TRACP-5 B）亚型5 B的减少（图1a和图B），尽管它们的“双重效应”小于初治组。然而，与DMAb ≤ 12个月组相比，DMAb> 12个月组的PINP和TRACP-5 b均快速且更高地增加。在ROMO治疗12个月后，与所有其他组相比，初治组显示LS的BMD增加显著更高（图1 c和d）。与BP组和DMAb≤ 12个月组相比，初治组的TH BMD往往显示出更高的增加，但与DMAb> 12个月组相比，增加显著更高。违背
We read the paper written by Tominaga et al.[1] entitled “Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment” in the June issue of Osteoporosis International with great interest. Their conclusion indicated that treatment with oral bisphosphonate (BP) or denosumab (DMAb) for> 1 year attenuated the effect of romosozumab (ROMO) evaluated by the change of bone mineral density (BMD) in lumbar spine (LS), but not in total hip (TH). This finding was impactful, particularly in the treatment initiation and duration of BP and DMAb. We reported on the treatment response of ROMO [2, 3], and analyzed data similarly regarding the effects of previous osteoporosis treatment duration. In their report [1], mean age was 77.2 years, and BMD T-score was LS=− 2.4, TH=− 2.4. However, mean age was 74.5 years, and BMD T-score was LS=− 3.1, TH=− 2.6 in our group (Supplementary Table 1)[2]. Duration of previous BP orDMAb treatment≤ 12 months was similar. Patients were divided into five groups: previous treatment naïve (n= 55) group, BP≤ 12 months group (n= 10), BP> 12 months group (n= 27), DMAb≤ 12 months group (n= 16), and DMAb> 12 months group (n= 29). Both BP groups, regardless of previous BP duration, showed a similar transient increase in total N-terminal type I procollagen propeptide (PINP), and a decrease in isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b)(Fig. 1a and b), although their “dual effect” was smaller than the naïve group. However, there was a rapid and higher increase in both PINP and TRACP-5b in the DMAb> 12 months group compared to the DMAb≤ 12 months group. The naïve group showed a significantly higher BMD increase in LS compared to all other groups (Fig. 1 c and d) after 12 months of ROMO treatment. The naïve group tended to show a higher increase compared to BP groups and the DMAb≤ 12 months group concerning TH BMD, but the increase was significantly higher in comparison to DMAb> 12 months group. Contrary to the
影响因子：
3.3
作者：
Miyauchi, Akimitsu;Hamaya, Etsuro;Shimauchi, Junichiro
通讯作者：
Shimauchi, Junichiro
既往骨质疏松症治疗持续时间对罗莫佐单抗治疗效果的影响
影响因子：
4
作者：
A. Tominaga;K. Wada;K. Okazaki;H. Nishi;Y. Terayama;Y. Kodama;Y. Kato
通讯作者：
Y. Kato
影响因子：
4
作者：
Ebina, K.;Etani, Y.;Nakata, K.
通讯作者：
Nakata, K.